Response to crizotinib in advanced intrahepatic cholangiocarcinoma with ZKSCAN1-MET fusion and MET amplification: case reports and literature review
Abstract Intrahepatic cholangiocarcinoma (ICC) is the second most prevalent liver cancer after hepatocellular carcinoma and is characterized by high malignancy and poor prognosis. Gemcitabine combined with cisplatin is the standard first-line therapy for metastatic or unresectable ICC. The combinati...
Salvato in:
| Autori principali: | , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Springer
2025-06-01
|
| Serie: | Discover Oncology |
| Soggetti: | |
| Accesso online: | https://doi.org/10.1007/s12672-025-02930-4 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|